USP<1> Injections and Implanted Drug Products (Parenterals)—Product Quality Tests

USP <1> defines the core product-quality requirements for injections and implanted parenteral drug products. For products labeled to comply with USP–NF, the provisions of <1> and its cross-referenced chapters are legally enforceable when cited in a monograph. The chapter consolidates essential tests addressing safety, identity, strength, quality, and purity. Manufacturers must apply the relevant tests as appropriate to the dosage form and monograph requirements.

• Applicability & hierarchy: Requirements in <1> apply to injections and implanted parenterals (solutions, suspensions, emulsions, lyophilized products) as applicable; individual monographs and labeling control specifics. Chapters <1000 are requirements; >1000 are informational unless referenced.

• Core product-quality tests referenced by <1> (apply as appropriate):

  • Sterility: <71> Sterility Tests (validated alternatives allowed per USP guidance).

  • <85> Bacterial Endotoxins Test is the standard method. <151> Rabbit Pyrogen Test is permitted only in rare, justified cases where BET cannot be validated or non-endotoxin pyrogens are a specific concern.

  • Visible particulates: <790> Visible Particulates in Injections (“essentially free of visible particulates”).

  • USP 〈788〉 Particulate Matter in Injections

  • pH: <791> 

  • Osmolality/Osmolarity: <785>.

  • Deliverable volume: <698> (volume obtainable from the container).

  • Container–closure integrity: <1207> to ensure sterility maintenance; USP <1207> provides recommended approaches, with deterministic methods preferred

  • Dose delivery/content uniformity (where relevant): <905> Uniformity of Dosage Units (applies only to certain parenteral presentations, e.g., suspensions/emulsions or doses withdrawn from a container).

  • Extractables/leachables risk assessment (as appropriate): <1663>/<1664>.

• Labeling: Conform to <7> Labeling and any monograph-specific statements.

• Not all tests apply to every product; justification and risk-based application are expected.